QualityStocksNewsBreaks Archives - Page 241 of 1507

TuesdayApr 02, 2024 3:09 pm

QualityStocksNewsBreaks – Astrotech Corp. (NASDAQ: ASTC), Subsidiary Set to Spotlight Tracer 1000 Trace Detector at Leading Security Trade Event

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, will be showcasing the TRACER 1000 Narcotics Trace Detector (“NTD”) and Explosives Trace Detector (“ETD”) at the International Security Conference and Exposition. Known as ISC West, the conference and expo is slated to run April 9–12, 2024, in Las Vegas; the event is the one of the leading comprehensive security trade events in the nation and will be attended by key security and public-safety professionals. A high-performance laboratory instrument powered by Astrotech Mass Spectrometer Technology(TM), the TRACER 1000 can detect trace levels of narcotics…

TuesdayApr 02, 2024 3:01 pm

QualityStocksNewsBreaks – Danimer Scientific Inc. (NYSE: DNMR) Secures ~$15M in Registered Direct

Danimer Scientific (NYSE: DNMR) is a leading next- generation bioplastics company focused on the development and production of biodegradable materials. The company recently announced the closing of its registered direct offering for the purchase and sale of 15,000,000 shares of common stock (or common stock equivalent in lieu thereof) at a purchase price of $1.00 per share (or per common stock equivalent in lieu thereof) and accompanying warrants to purchase up to an aggregate of 15,000,000 shares of common stock. Danimer secured approximately $15 million in gross proceeds, of which it intends to use the net for working capital and…

TuesdayApr 02, 2024 2:49 pm

QualityStocksNewsBreaks – HealthLynked Corp. (HLYK) Releases Q4, FY 2023 Financial Report Reflect Focus on Core Healthcare Network

HealthLynked (OTCQB: HLYK), a leader in healthcare networking and technological innovation, is reporting financial results for Q4 and full year ended Dec. 31, 2023. A highlight of the report includes that, based on “strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.” The report noted that the company’s strategic focus and technological innovations are paving the way for an optimistic outlook with optimization of operational expenses leading to a 52% cut in operational losses. In…

TuesdayApr 02, 2024 1:35 pm

QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) in a humanized mouse model. “These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies,” said Rodney Varner, president, chairman and CEO at Genprex. “We…

TuesdayApr 02, 2024 1:09 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report included that Berubicin, the company’s lead program, has passed preplanned interim futility analysis milestones with a recommendation to proceed without modification into a potentially pivotal glioblastoma multiforme (“GBM”) study, and enrollment for the Berubicin study has been completed with topline data expected in first half…

TuesdayApr 02, 2024 12:21 pm

QualityStocksNewsBreaks – Zoned Properties Inc. (ZDPY) Refocusing Investment Portfolio to Potentially Unlock Equity

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, is seeking to capitalize on the U.S. cannabis industry’s burgeoning future by targeting commercial properties with the potential to be acquired and rezoned or permitted for specific purposes. “Zoned Properties maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois, with each of its leased properties occupied by commercial cannabis-linked businesses. The company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail…

TuesdayApr 02, 2024 11:40 am

QualityStocksNewsBreaks – Astiva Health Setting New Standard for Patient-Centric Care

Astiva Health, a leading provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods. “At the core of Astiva Health’s innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences, needs and values guide their care plans… A critical element in Astiva Health’s strategy is the development of a supportive health community. This community – encompassing healthcare professionals, family, caregivers, and peer groups – provides…

MondayApr 01, 2024 1:51 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Begins Manufacturing for Major Sports Brand Licensee

Nutriband (NASDAQ: NTRB, NTRBW), a pharmaceutical company with a specific focus on transdermal technologies, today announced it has been engaged by and received a first order from Fit For Life Group (“FFL”), a major brand license holder. Nutriband expects a fully executed supplier agreement to follow. Under the agreement Nutriband’s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer. “This purchase order from FFL allows Nutriband and our contract manufacturing subsidiary, Active Intelligence, to once again demonstrate our capabilities in the development and manufacturing of innovative products,” said Gareth Sheridan, CEO of Nutriband. “We are excited to continue…

ThursdayMar 28, 2024 3:42 pm

QualityStocksNewsBreaks – Diamond Lake Minerals Inc. (DLMI) Positioned ‘Ahead of the Curve’ in Tokenization

Diamond Lake Minerals (OTC: DLMI) is a leading multi-strategy operating company specializing in developing and supporting digital assets and SEC-registered security tokens. The company was featured in a new Benzinga Crypto article that discussed DLMI’s favorable positioning in tokenization attributed to its innovative technology, infrastructure and leadership. “DLMI has spent a substantial amount of time and resources under the leadership of its CEO Brian J. Esposito working on the program of converting real estate assets into blockchain-based digital tokens in its ecosystem… A big part of DLMI’s strategy was its recent acquisition of Avrio Worldwide PBC, a registered market infrastructure…

ThursdayMar 28, 2024 2:50 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Capitalizing on ‘Overwhelming Interest’ to Focus on GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. “This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH technology including its new foray into GLP-1 drugs… This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage…

Site Search

Company Search

Category: QualityStocksNewsBreaks